CTI BioPharma (CTIC) Income Statement

Click line-items for a historical chart and %

License and contract revenue
Total revenues	4.43M
Research and development
Selling, general and administrative	15.22M
Total operating expenses	33.1M
Loss from operations	-28.66M
Investment and other income, net
Interest expense	-634K
Amortization of debt discount and issuance costs
Foreign exchange gain (loss)	-69K
Debt conversion expense
Other income (expense), net	-697K
Net loss before noncontrolling interest
Noncontrolling interest	178K
Net loss attributable to CTI	-29.18M
Dividends and deemed dividends on preferred stock
Net loss attributable to CTI common shareholders
Basic and diluted net loss per common share	-0.1
Shares used in calculation of basic and diluted net loss per common share

Entities mentioned with CTIC

View All Entities